MedTrace Logo

Physiological Intermolecular Modification Spectroscopy (PIMS) in Ulcerative Colitis With Golimumab

NCT02186886 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2014-07-10

No results posted yet for this study

Summary

Aim of this study is to determine wether the macromolecular spectral characteristic of ulcerative colitis patients - measured by Physiological Intermolecular Modification Spectroscopy (PIMS) - is a predictive factor for response to Simponi treatment

Conditions

Interventions

DRUG

Golimumab

Physiological Intermolecular Modification Spectroscopy

Sponsors & Collaborators

  • Kliniken im Naturpark Altmuehltal

    lead OTHER

Principal Investigators

  • Matthias G Breidert, MD · Naturpark Kliniken Altmuehltal

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02186886 on ClinicalTrials.gov